Citi analyst Carly Kenselaar initiated coverage of Travere Therapeutics with a Neutral rating and $7 price target. The analyst says the narrow statistical miss on the U.S. confirmatory endpoint in Travere’s Phase 3 PROTECT trial has brought Filsparib’s future approval status into question. However, the firm believes the PROTECT data provide consistent evidence of benefit on kidney function. Nonetheless, given the current regulatory uncertainty and its conservative expectations for the commercial ramp, it starts the stock at Neutral.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TVTX:
- Travere Therapeutics Reports Third Quarter 2023 Financial Results
- TVTX Upcoming Earnings Report: What to Expect?
- Travere Therapeutics to present data from clinical studies of sparsentan
- Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
- Travere Therapeutics to Report Third Quarter 2023 Financial Results
